Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.445 USD | +2.14% | 0.00% | +4.52% |
Apr. 17 | Wedbush Raises Price Target on Ardelyx to $14 From $13, Keeps Outperform Rating | MT |
Apr. 05 | Leerink Partners Initiates Coverage on Ardelyx With Outperform Rating, $14 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.52% | 1.47B | |
-2.29% | 103B | |
+0.55% | 95.71B | |
+1.69% | 22.02B | |
-16.88% | 20.9B | |
-9.30% | 17.85B | |
-41.01% | 16.21B | |
-14.60% | 15.52B | |
+3.29% | 13.86B | |
+34.58% | 12.04B |
- Stock Market
- Equities
- ARDX Stock
- News Ardelyx, Inc.
- Ardelyx to Launch Drug for Irritable Bowel Syndrome in Q2 2022